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Abstract Methods are described for producing an active amino- 
terminal domain of tissue inhibitor of metalioproteinases-1 (N- 
TIMP-1) from inactive protein expressed as inclusion bodies in 
E. coli. Yields exceed 20 mg per litre of bacterial culture. 
Activity measurements, CD spectroscopy and NMR spectros- 
copy of the lSN-labeled protein show that it is fully active, 
homogeneous in conformation and suitable for high-resolution 
structural analysis. The affinity of N-TIMP-1 for matrix 
metalloproteinases 1, 2 and 3 is 6-8-fold less than that of the 
recombinant full-length protein, indicating that deletion of the C- 
terminal domain reduces the free energy of interaction by < 10%. 
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1. Introduction 
Tissue inhibitors of metalloproteinases (TIMPs) play im- 
portant roles in regulating the activities of matrix metallopro- 
teinases (MMPs or matrixins) [1,2], a family of enzymes that 
are responsible for the breakdown of components of connec- 
tive tissue. Matrix turnover is an important aspect of many 
normal and pathological processes, such as growth, tissue 
remodeling, wound repair, and tumor metastasis. TIMPs con- 
sist of two domains, an amino-terminal inhibitory domain of 
about 120 amino acids through which they bind to an active 
MMP to form a tight (Ki < 1 nM), 1:1, non-covalent com- 
plex and a carboxy-terminal domain which is involved in in- 
teractions with progelatinases [3]. In addition to their inhibi- 
tory activities towards MMPs, TIMPs have also been reported 
to possess cell growth promoting activity [4-6]. 
Three members of the family of TIMP have been identified 
to date: TIMP-1, TIMP-2 and TIMP-3 [3,7-11]. The level of 
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overall amino acid sequence similarity between pairs of 
TIMPs is 2840% and 12 cysteinyl residues known to form 
six disulfide bonds are conserved in all TIMPs, each domain 
being stabilized by three disulfide bonds [12]. TIMP-1 is a 
glycoprotein with heterogeneous N-linked complex glycan 
units attached to Asn-30 and Asn-78 [7,13], whereas TIMP- 
2 and chicken TIMP-3 are not glycosylated [8,9]. The recom- 
binant human and mouse TIMP-3s expressed in NSO mouse 
myeloma cells, however, are secreted primarily as 27 kDa 
glycosylated forms [14]. A low resolution NMR solution 
structure of the inhibitory amino-terminal domain of TIMP- 
2 has been reported [12], which provides a basis for interpret- 
ing the results of structure function relationships in members 
of the TIMP family. 
Recombinant active forms of human TIMP-1 and TIMP-2 
and of the amino-terminal domains of TIMP-1 and TIMP-2, 
have been expressed in mammalian cells [15-17] and in bacu- 
lovirus-infected insect cells [18,19]. Eukaryotic expression sys- 
tems are often preferred for producing correctly processed and 
folded recombinant forms of mammalian proteins but micro- 
bial expression systems have advantages in terms of yield, cost 
and they are more easily used for producing mutant proteins. 
With the goal of developing an expression system that is 
suitable for high yield protein production and mutagenesis 
studies of the inhibitory domain of human TIMP-1 (N- 
TIMP-1), we have chosen to use pET vectors and an E. coli 
host. The overexpression of proteins in E. coli leads to the 
formation of inclusion bodies, which are easily isolated but 
require treatment to generate native protein [20]. Since TIMP- 
1 does not require glycosylation to be active [21,22], the ab- 
sence of glycosylation i an E. coli system was not perceived 
to be problematic. Previous work has shown that mouse 
TIMP-1 [23] human TIMP-1 [24,25] and human TIMP-2 
[26] are expressed as inclusion bodies in E. coli and can be 
folded in vitro, but the bacterial expression of the amino- 
terminal domain of TIMP-1 has not been described. Here 
we describe the expression of the amino-terminal domain of 
human TIMP-1 (N-TIMP-1) as inclusion bodies, a modified 
high yield in vitro folding procedure that avoids the produc- 
tion of large volumes of very dilute solutions of protein, and 
the functional and physical properties of the protein deter- 
mined by CD spectroscopy and 2D NMR spectroscopy of 
the l~N-substituted protein. The small size of the isolated in- 
hibitory domain, the high folding yield and conformational 
homogeneity of the product indicate that our E. coli expressed 
N-TIMP-1 is a suitable subject for structural analysis by mul- 
ti-nuclear NMR and X-ray crystallography. 
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2. Materials and methods 
2.1. Materials 
MacroPrep 50Q anion exchange resin and Affi-Gel 10 were from 
BioRad Laboratories. CM-52 cation exchange resin was from What- 
man and Sephacryl S-300 and S-200 were from Pharmacia. [15N]H4CI 
and deuterated reagents for NMR spectroscopy were purchased from 
Cambridge Isotope Laboratories, Andover, MA. The pET3a expres- 
sion vector was from Novagen and restriction enzymes were from 
New England Biolabs. Taq DNA polymerase was from Promega. 
Bis(2-hydroxyethyl) disulfide is from Aldrich Chemical Co., Milwau- 
kee, Wisconsin. The ftuorogenic substrate Mca-Arg-Pro-Lys-Pro-Val- 
Glu-Nva-Trp-Arg-Lys(Dnp)-NH2 was a gift from Dr. G.B. Fields, 
University of Minnesota, Minneapolis, MN, while Mca-Pro-Leu- 
Gly-Leu-Dpa-Ala-Arg-NH2 was from Bachem Bioscience Inc., King 
of Prussia, PA. Oligonucleotides were synthesized by Dr. R. Werner, 
Univ. of Miami School of Medicine. Human TIMP-1 cDNA was 
kindly supplied by Dr. Masanobu Naruto of Toray Industries, Ka- 
makura, Japan. The mammalian expression vector, pEE-14 was gen- 
erously provided by Celltech Inc., Slough, UK. Specific polyclonal 
anti-(human TIMP-1) antibody was prepared as described previously 
[27]. ProMMP-1, proMMP-2 and proMMP-3 were isolated from the 
culture medium of human rheumatoid synovial cells stimulated with 
rabbit macrophage-conditioned medium and activated as described 
previously [28-30]. The catalytic domain of MMP-3 (MMP-3(AC)) 
was obtained by expressing proMMP-3(AC) in E. coli using a 
MMP-3 cDNA in which a stop codon is substituted for Pro-256 
(Suzuki et al., in preparation). ProMMP-3(AC) was activated to 
MMP-3(AC) using 1.5 mM 4-aminophenylmercuric acetate. 
2.2. Amplification of N-TIMP1 cDNA 
The cDNA encoding N-TIMP-1 was amplified by PCR using three 
primers. The first amplification was carried out using the 5' primer: 
5'CTCACTACGTCATATGTGCACCTGTGTCCCCA3' which con- 
tains an NdeI cloning site and Met-l, and a mutagenic primer: 
5'GGATAAACAGGGAATTCCTGTTCATTCCTCACAGCC-3' 
which introduces a stop codon at the position corresponding to resi- 
due 127 of TIMP-1 so that only the N-terminal domain of TIMP-1 
will be expressed. The product of this reaction was gel purified and 
used in the second amplification as a megaprimer [31] with the 3' 
primer: 5'GAATTGTCGCGGATCCTCAGGCTATCTGGAY 
which contains a BamHI cloning site. PCR reactions were carried 
out using a Perkin Elmer/Cetus thermocycler for 25 cycles at 94°C 
for 1 min, 50°C for 1 min and 72°C for 1.5 min. To circumvent a 
difficulty in cleaving the PCR product at the NdeI site, it was firstly 
ligated to a T-vector (pUC19 plasmid opened at polycloning site by 
Sinai with extra 'T' bases added using DNA polymerase), trans- 
formed into DH5c~ and amplified. The plasmid DNA containing the 
TIMP-1 cDNA insert was digested with BamHI and NdeI and the 
TIMP-1 cDNA was cloned into the pET3a vector as follows. 
2.3. Construction of the expression vector 
The BamHI and NdeI sites in the pET3a vector are only 12 bases 
apart so that vector that has been cleaved at both restriction sites is 
not readily separable from partially cleaved vector. Thus, pET3a was 
first cleaved with PstI and BamHI, to generate the 1264 base fragment 
A and with PstI and NdeI to generate the 3338 base fragment B. 
Fragments A and B were purified from the digests by gel electrophor- 
esis. A ligation reaction was then carried out with fragments A and B 
and the BamHI/NdeI-cleaved coding region from the TIMP-1 cDNA. 
This produced the pET3a-N-TIMP1 expression vector, pNT1, which 
was used to transform BL21(DE3) cells for N-TIMP1 expression. 
2.4. Expression of N-TIMP-1 
Host cells with the pNT1 vector were grown in LB medium (1-6 1) 
containing 200 I.tg/ml ampicillin at 37°C until the A600nm reading 
reached 0.6-0.8. At this point expression was induced by the addition 
of IPTG to 0.4 mM. Growth was continued for an additional 3 h. 
Cells were harvested by centrifugation and lysed using lysozyrne and 
deoxycholate following a standard procedure [32]. Inclusion bodies 
were collected by centrifugation and washed and the protein was 
extracted with 8 M urea containing 20 mM Tris-HC1, pH 8.5, and 
10 mM DTT. SDS-PAGE indicates that N-TIMP-1 (Mr 14000) re- 
presents >90% of the protein in this extract. However, this material 
also contained a large amount of DNA which interferes with the 
folding process of N-TIMP-1 (p I= 10.5) as they interact during re- 
moval of the urea by dialysis. To remove DNA, the extract was first 
passed through a column of MacroPrep 50Q anion exchange resin 
equilibrated with 20 mM Tris-HC1, pH 8.0, containing 8 M urea, to 
remove free anionic macromolecules. The flow-through fraction was 
then applied to a column (5.5×28 cm) of Sephacryl S-300 in 8 M 
urea, 20 mM Tris HC1, 0.5 M NaCI, pH 7.5, to separate N-TIMP-1 
from high molecular weight contaminants. 
2.5. Expression of [15N]N-TIMP-1 
E. coli BL21(DE3) cells, transformed with the pNT1 vector, were 
inoculated into LB medium and grown overnight at 37°C. The cells 
were collected by centrifugation, washed with M9 minimal medium 
[32] and then grown with shaking at 37°C in M9 minimal medium 
containing [15N]H4C1. After approx. 12 h, N-TIMP-1 expression was 
induced by adding IPTG (0.4 mM) and the cells grown for another 12 
h prior to harvesting. [15N]N-TIMP-1 was isolated and folded as 
described below. 
2.6. In vitro folding of N-TIMP-1 
Fractions containing N-TIMP-1 from Sephacryl S-300 were pooled 
and diluted to <100 ~tg protein/ml with 20 mM Tris-HC1, pH 8.0, 
containing 8 M urea. This solution was treated with cystamine (50 
mM) overnight at 4°C to form mixed disulfides between protein and 
cystamine. The solution was then dialyzed for against wo changes (24 
h each) of 15 vols. of folding buffer (50 mM Tris-HC1, pH 7.5, con- 
taining 150 mM NaCI, 10 mM CaC12, 5 mM B-mercaptoethanol and 
1 mM bis(2-hydroxyethyl) disulfide), followed by two changes (4 h 
each) of 20 mM Tris-HCl, pH 7.0 [33]. The protein was finally con- 
centrated and further purified by cation exchange chromatography 
with columns (2× 10 cm) of CM-cellulose CM-52 equilibrated with 
20 mM Tris-HCl, pH 7.0. After washing the CM-52 with 2 vols. of 
equilibration buffer, N-TIMP-1 was eluted with a linear gradient (500 
ml) from 0 to 0.5 M NaC1 in the same buffer at a flow rate of 2 ml/ 
min. 
2. 7. Expression of TIMP-1 in mammalian cells 
Human TIMP-1 cDNA was cloned into the expression vector, pEE- 
l4, between the human CMV promoter and the SV 40 early polya- 
denylation signal. The pEE-14 vector contains the glutamine synthe- 
tase gene which was used as an amplifiable marker in Chinese hamster 
ovary (CHO K-l) cells. Cells producing high levels of TIMP-1 were 
selected in glutamine-free medium supplemented with methionine sul- 
foximine as described by Cockett et al. [34]. The recombinant TIMP-1 
secreted into the culture medium was purified with an immunoabsor- 
bant column of Am-Gel 10 coupled with sheep anti-(human TIMP-1) 
IgG followed by gel filtration with Sephacryl S-200. Recombinant 
TIMP-1 was homogeneous on SDS-PAGE. 
Table 1 
Inhibition constants (Ki values) of recombinant TIMP-1 and N-TIMP-1 for MMP-1, MMP-2 and full-length and truncated forms of MMP-3 
Metalloproteinase Inhibitor 
TIMP-1 (K~, nM) N-TIMP-1 (Ki, nM) 
Ratio (N-TIMP-1/TIMP-1) 
MMP-1 0.25±0.03 
MMP-2 0.14±0.002 
MMP-3 0.24±0.02 
MMP-3~C) 0.25±0.04 
1.48±0.35 5.9 
1.11±0.13 7.9 
1.40±0.02 6.3 
1.92±0.08 7.8 
Ki values are + S.D. 
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2.8. Assay of inhibitory activity 
The inhibitory activity of recombinant TIMP-1 and N-TIMP-1 pre- 
parations were assayed by preincubating with MMP-3 to form pro- 
teinase-inhibitor complexes. The residual MMP-3 activity in these 
samples was assayed using S-[3H]carboxymethylated human transfer- 
rin as described by Nagase [35]. 
2.9. CD spectrum of TIMP-1 
Near-and far-UV CD spectra of TIMP-1 and recombinant N- 
TIMP-1 were determined with a JASCO J-710/720 spectropolarimeter. 
20 spectra were scanned for each sample at a speed of 100 nm/min 
which were subsequently averaged and smoothed. Near-UV CD spec- 
tra (250-320 nm) were determined using a cell with a path length of 
1 cm, and far-UV spectra (200-250 nm) using a cell with a path length 
of 0.1 cm. Protein samples were dissolved in 20 mM Tris-HC1, pH 7.0, 
containing 0.2 M NaC1. 
2.10. NMR spectra of [15N]N-TIMP-1 
NMR spectra of 15N-enriched N-TIMP-1 were acquired using 
AMX-500 or DRX-500 spectrometers (Bruker Analytische Messtech- 
nik GMBH, Karlsruhe, Germany) using either a 5 mm Bruker inverse 
detection probe or a 8 mm triple resonance probe (Nalorac Cryo- 
genics Corporation, Martinez, CA). 
2.11. Kinetic studies 
Synthetic fluorogenic peptide substrates, Mca-Arg-Pro-Lys-Pro- 
Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2 for MMP-3 [36] and Mca- 
Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, for MMP-1 and MMP-2 [37] 
157 
were used to assay TIMP activity as described previously [36,37]. 
Assays of the inhibition of each of the above MMPs by both recom- 
binant full-length TIMP-1 and N-TIMP-1 was carried out by prein- 
cubating the MMP (0.1 to 1 nM) and TIMP (0-50 nM) in 50 mM 
Tris-HC1, pH 7.5, containing 0.15 M NaCI, 10 mM CaC12 and 0.02% 
Brij at 37°C for 1 h. The time required for equilibration was deter- 
mined by following the progress of inhibition after mixing MMPs and 
TIMP at concentrations in the range used in the assay. An aliquot (60 
p.1) of substrate (15 gM) was then added to 540 ~tl of the preincubated 
MMP-TIMP mixture and activity was measured at 37°C by following 
product release with time. Inhibited rates were obtained from the 
initial 20 min of the reaction profile where product release was linear 
with time. Fluoresence was measured using a Perkin Elmer LSh0 
fluorimeter. Ki values were calculated using the treatment of data 
for slow tight-binding inhibitors described by Morrison and Walsh 
[38]. The values used for the total concentration of TIMP were those 
of the preincubation mixture. Because of the slow dissociation rate for 
TIMP from complexes with MMPs, and the low substrate concentra- 
tion (1.5 I.tM) relative to the Kin, no attempt was made to correct for 
the 10% dilution between preincubation and assay or for competition 
between TIMP and substrate for binding to MMPs. 
3. Resu l ts  
N-TIMP-1 was expressed as inclusion bodies to a level of 
20% of the total wet weight of the E. coil After extraction, 
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Fig. 1. Purification of folded N-TIMP-1 by cation exchange chromatography with CM-cellulose CM-52. Chromatography was carried out as 
described in section 2.6. TIMP activity against MMP-3 was assayed as described in Section 2.8. (zx--zx) Absorbance at 280 nm; (O'"O) TIMP 
activity, which is expressed as [3H]carboxymethylated transferrin (cpm) released by MMP-3 alone-(cpm) released by MMP-3 incubated with N- 
TIMP-1. The inset shows the results of SDS-PAGE under reducing conditions of recombinant TIMP-1 (lane 1) and N-TIMP-1 (lane 2). The 
molecular weights of standard molecular weight markers are given on the left. 
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unfolded N-TIMP-1 was purified by ion exchange chromatog- 
raphy and gel filtration with Sephacryl S-300 in the presence 
of 0.5 M NaC1. Electrophoresis with agarose gels and SDS- 
PAGE polyacrylamide g ls, respectively, showed that signifi- 
cant amounts of DNA and a mixture of proteins of different 
sizes were present in the void volume peak, while the second 
A280nm peak contained a reasonably pure form of unfolded N- 
TIMP-1 (Mr 14000). 
Fractions containing N-TIMP-1 from the Sephacryl S-300 
separation were subjected to the dialysis procedure described 
in section 2 to generate native protein. When this was carried 
out using protein concentrations >100 gg/ml, a large propor- 
tion of the protein precipitated during dialysis; precipitation 
was greatly reduced by reducing the protein concentration to
50 p.g/ml. Folded N-TIMP-1 was subsequently concentrated 
and purified by chromatography with CM-52 (Fig. 1) to give a 
single peak in which protein concentration and activity coin- 
cided. This material gave a single band of 14 kDa on SDS- 
PAGE whereas the CHO cell expressed recombinant full- 
length TIMP-1 was estimated to be 28.5 kDa (Fig. 1). Both 
proteins were positive on Western blotting with anti-TIMP-1 
antiserum (data not shown). 
The structural state of the in vitro folded N-TIMP-1 was 
investigated by CD and NMR spectroscopy. The near-and 
far-UV CD spectra of N-TIMP-1 are similar, but distinct 
from those of the full-length TIMP-1 obtained by mammalian 
expression, both proteins having positive complex spectra in 
the near-UV range with a maximum around 290 nm and 
typical negative llipticities in the far-UV range with minima 
at 208 nm (Fig. 2). 
Recombinant TIMP-1 and N-TIMP-1 showed similar high 
stabilities to thermal denaturation. After heating solutions of 
either protein (10 I.tg/ml) at 95°C for 15 rain full activity was 
restored (>95%) on cooling to room temperature. In contrast, 
when the unfolding of N-TIMP-1 was monitored by near-UV 
CD ellipticity thermal unfolding was observed between 45 and 
60°C. In this case, unfolding was accompanied by precipita- 
tion and was irreversible; neither the near-nor far-UV spec- 
trum was restored on cooling to 30°C after heating to 60°C. 
This appears likely to reflect the fact that a far higher con- 
centration (400 ~tg/ml) was used in the CD study which en- 
hances the aggregation of unfolded or partially folded forms 
of the protein. At pH 2.0 the spectrum is reduced in magni- 
tude but not eliminated indicating a higher level of stability to 
acid. 
NMR spectra determined for l~N-substituted N-TIMP-1 
indicate that the protein folded from inclusion bodies is 
homogeneous in conformation. A homogeneous preparation 
is expected to have one backbone amide NMR peak for each 
non-proline residue. At least 92% of the 119 possible back- 
bone amide peaks are reproducibly resolved in the 2D spectra 
correlating amide protons with the attached 15N nuclei of 
[15N]N-TIMP-1 by heteronuclear multiple quantum coherence 
(HMQC) (Fig. 3) and heteronuclear single quantum coherence 
(HSQC) spectra (data not shown). Furthermore, ssentially all 
of the expected side chain peaks from Asn, Gin and Arg 
residues (the Arg peaks are not plotted in Fig. 3) can be 
counted, provided presaturation of the water resonance is 
avoided. The spectral dispersion, linewidths, and patterns of 
NOEs among backbone amide and c~ protons (not shown) 
suggest hat N-TIMP-1 is correctly folded and well suited 
for high resolution structural studies. 
In agreement with these results, titration of MMP-3 (45 
nM) with increasing concentrations of N-TIMP-1 (Fig. 4) 
showed that full inhibition was acheived at a 1.08:1 molar 
ratio of inhibitor to enzyme, indicating that all molecules in 
the N-TIMP-1 preparation are active. Equilibrium inhibition 
constants for the recombinant full-length TIMP-1 and recom- 
binant N-TIMP-I for MMP-1, MMP-2 and the full-length 
MMP-3 (45 kDa) and the catalytic domain of MMP-3 (23.5 
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Fig. 3. HMQC spectrum of ]SN-enriched N-TIMP-1 at 500 MHz. Protein (0.6 raM) was dissolved in 92% H20/8% D20 containing 25 mM 
deuterated sodium acetate, pH 6.0 and 20 mM CaCI2. Water suppression was achieved using 1-1 excitation and 1-1 refocusing pulses instead 
of presaturation, as described by Sklenar and Bax [39]. 
kDa)  were determined using quenched fluorescent peptide 
substrates as described. The results, summarized in Table 1, 
show that Ki values of N-TIMP-1 for MMP-1, MMP-2 and 
full-length and truncated forms of MMP-3 are in the nano- 
molar range but they are 6-8 times higher than those of full 
length TIMP-1. 
4. D iscuss ion 
The aim of the present project was to develop a system for 
the expression and mutational analysis of the N-terminal do- 
main of TIMP-1 which provides ufficient protein for proper 
physical and structural characterization. Other groups have 
reported mammalian expression systems for full length and 
C-terminally truncated forms of TIMP-1 and TIMP-2 [15- 
17] The expression of full-length TIMP-1 in E. coli as inclu- 
sion bodies together with procedures for folding and isolation 
of active protein have been described by others [23-26]. 
Although the production of active protein in high yield has 
been described, Cocuzzi et al. [23] reported that their recom- 
binant protein preparations have a high proportion of non- 
native molecules. This may be also the case with the expres- 
sion system described by Kleine and co-workers [25] since 
their E. eoli expressed recombinant TIMP-1 has a 7-fold lower 
affinity for neutrophil collagenase (MMP-8) as compared with 
the natural protein. Although the properties of truncated 
forms of TIMP-1 expressed in mammalian cells have been 
described by other investigators [15], a bacterial expression 
system for N-TIMP-1 was not developed previously. 
The procedure described here utilizes the high level expres- 
sion provided by pET vectors in conjunction with a separa- 
tion and folding protocol. The method reproducibly provides 
high yields of native protein (about 20 rag/l) and is more facile 
in generating a more concentrated solution of folded protein 
than in methods previously described for full length TIMP-1. 
An important aspect of the procedure is the partial purifica- 
tion of the protein extracted from inclusion bodies in the 
denatured state prior to folding, a step that removes anionic 
materials uch as DNA which may associate strongly with the 
unfolded basic TIMP-1 molecule and stabilize the unfolded 
state under folding conditions. 
CD spectroscopy shows that purified N-TIMP-1 has a spec- 
trum that is similar to but distinct from that of full-length 
TIMP-1 expressed in a eukaryotic system (Fig. 2). N-TIMP- 
1 unfolds reversibly when heated to 95°C at low concentra- 
tions, but denatures and aggregates at lower temperatures 
when unfolding was monitored by CD spectroscopy at 
much higher concentrations. This contrasts with the reversible 
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Fig. 4. Titration of MMP-3 with recombinant TIMP-1 and N- 
TIMP-1. MMP-3 (45 kDa) was incubated with equal volumes of so- 
lutions of TIMP-1 solution at different concentrations at 37°C for 
30 min. and the residual MMP-3 activity was measured using S- 
[3H]carboxymethylated transferrin. The final concentration of 
MMP-3 in the assay was 45 nM. (e) Full-length CHO K1 expressed 
TIMP-1 ; (©) E. coli expressed N-TIMP-1. 
nature of the chemical denaturation of mammalian-expressed 
glycosylated and unglycosylated forms of N-TIMP-1 by gua- 
nidine HC1 described by Williams and co-workers [17] and 
indicates that stability measurements of N-TIMP-1 variants 
are best determined by reversible chemical denaturation rather 
than by thermal unfolding. 
Bacterial expression systems provide an economical means 
of generating isotopically substituted protein for multinuclear 
NMR studies, by growth on minimal medium containing ap- 
propriate isotopically labeled precursors as the sole source of 
protein nitrogen and carbon. NMR studies of 15N-enriched 
N-TIMP-1 generated in this fashion has provided strong evi- 
dence that the in vitro folded protein is homogeneous in con- 
formation, as well as being a promising subject for the deter- 
mination of its solution structure by multinuclear NMR. 
Other investigators have reported that N-TIMP-1 appears 
to have a lower inhibitory activity than full-length TIMP-1 for 
some metalloproteinases, based on measurements of associa- 
tion rate constants [3,15,16,40], but a direct comparison of Ki 
values for the two inhibitors with the same MMPs under the 
same conditions has not been reported. Our results, using 
recombinant forms of the two proteins how that N-TIMP-1 
is lower in affinity for MMP-1, MMP-2 and MMP-3 by fac- 
tors of 6-8. Although Baragi et al. [41] reported that C-term- 
inal domain-truncated MMP-3 has a reduced affinity for 
TIMP-1 compared with full-length MMP-3, our data shows 
that the Ki values of TIMP-1 (and N-TIMP-1) for MMP-3 
and MMP-3(AC) are closely similar. The lack of involvement 
of the C-terminal domain of MMP-3 in the interaction with 
TIMP-1 has also been indicated by the similarity of the rate 
constants for the association of TIMP-1 with the two forms of 
MMP-3 [40]. However, our study indicates that the Ki values 
for N-TIMP-1 for both MMP-3 and MMP-3(AC) are 6-8 fold 
higher than the corresponding parameters for TIMP-1. This 
suggests that the C-terminal domain of TIMP-1 makes some 
contribution to the interaction with the catalytic domain of 
MMP-3. It should be noted, however, that when the Ki values 
are used to calculate Gibbs free energy changes (AG) asso- 
ciated with the TIMP-MMP interactions (AG =-RT lnK i )  
the difference between the two-domain full-length TIMP-1 
and the single-domain N-TIMP-1 for binding to these three 
proteases i only 8 9% of the total free energy associated with 
the TIMP-1-MMP interaction (about 1 out of 13 kcal/mol). 
Therefore, contacts between these metalloproteinases and the 
C-terminal domain of TIMP-1 in these cases play only a min- 
or role in stabilizing the complex. 
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